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Metabolic Alterations: A Biomarker for Radiation-
Induced Normal Brain Injury—An MR Spectroscopy
Study
P.C. Sundgren, MD, PhD,1* V. Nagesh, PhD,2 A. Elias, MD,1 C. Tsien, MD,2
L. Junck, MD,3 D.M. Gomez Hassan, MD, PhD,1 T.S. Lawrence, MD,2
T.L. Chenevert, PhD,1 L. Rogers, MD,3 P. McKeever, MD, PhD,4 and Y. Cao, PhD1,2
Purpose: To assess if interval changes in metabolic status
in normal cerebral tissue after radiation therapy (RT) can
be detected by 2D CSI (chemical shift imaging) proton spec-
troscopy.
Materials and Methods: Eleven patients with primary
brain tumors undergoing cranial radiation therapy (RT)
were included. 2D-CSI MRS was performed before, during,
and after the course of RT with the following parameters:
TE/TR 144/1500 ms, field of view (FOV) 24, thickness 10
mm, matrix 16  16. The metabolic ratios choline/creatine
(Cho/Cr), N-acetylaspartate (NAA)/Cr, and NAA/Cho in
normal brain tissue were calculated.
Results: NAA/Cr and Cho/Cr were significantly decreased
at week 3 during RT and at 1 month and 6 months after RT
compared to values prior to RT (P  0.01). The NAA/Cr ratio
decreased by 0.19  0.05 (mean  standard error [SE]) at
week 3 of RT, 0.14  0.06 at the last week of RT, 0.14 
0.05 at 1 month after RT, and 0.30  0.08 at 6 months
after RT compared to the pre-RT value of 1.43  0.04. The
Cho/Cr ratio decreased by 0.27  0.05 at week 3 of RT,
0.11  0.05 at the last week of RT, 0.26  0.05 at 1
month after RT and 0.25  0.07 at 6 months after RT from
the pre-RT value of 1.29  0.03. Changes in Cho/Cr were
correlated with the interaction of the radiation dose and
dose-volume at week 3 of RT, during the last week of RT
(P  0.005), and at 1 month after RT (P  0.017).
Conclusion: The results of this study suggest that MRS
can detect early metabolic changes in normal irradiated
brain tissue.
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EVERY YEAR about 22,000 new cases of primary be-
nign and malignant brain neoplasms are diagnosed in
the United States (1). The incidence of both malignant
and benign tumors of the central nervous system has
been increasing in the older population, while remain-
ing stable or even decreasing in younger individuals (2).
Cranial radiation therapy (RT) is widely used to retard
tumor growth and proliferation. Cranial RT is known to
affect the central nervous system, resulting in delayed
neurological complications (3–5) and neurocognitive
deficits in long-term survivors. The incidence of radia-
tion necrosis after conventional therapy ranges from
5%–24% (6). The delayed neurological symptoms in-
clude functional and cognitive impairments, including
deficits in learning, working memory, executive func-
tion, vision, and motor function (7–10), and eventually
dementia. On conventional MRI the effects of radiation
on brain tissue are evident in some patients as early as
2–6 months after completion of RT as signal abnormal-
ity in white matter (5). These changes are defined as
early delayed radiation-induced injuries. Periventricu-
lar white matter abnormality is observed, but usually
not until 12–18 months post-RT (5,11). Changes ob-
served in animal models (12–14) and postmortem hu-
man brain specimens (15) include brain inflammation,
demyelination of white matter, breakdown of the blood–
brain barrier, and an array of neurotoxic effects (16).
Retrospective studies have noted a spatial relationship
between local RT dose and the changes seen on com-
puted tomography (CT) / magnetic resonance imaging
(MRI) (5,17). Furthermore, a previous study revealed
that after RT, normal-appearing large white matter
bundles such as genu and splenium of the corpus cal-
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losum show progressive structural degradation that is
evident initially in high-dose regions and later becomes
evident beyond the high-dose regions (18).
Magnetic resonance spectroscopy (MRS), a technique
for noninvasive measurement of chemical substances
(metabolites) in the brain, has proven to be a useful tool
in the evaluation of recurrent contrast-enhancing le-
sions in patients previously treated for primary neo-
plasms by helping to differentiate recurrent tumor from
radiation necrosis (19–21). It is useful as a prognostic
tool during tumor treatment (22), in evaluation of
changes in the brain after prophylactic RT for acute
leukemia (23,24), and in assessment of late delayed
radiation-induced effects (25,26). However, to our
knowledge only a few prospective studies evaluating
interval changes in metabolic activity in normal-ap-
pearing brain parenchyma during and following cranial
RT for primary brain neoplasm have been published.
Most used is single voxel 1H-MRS technique with only a
limited part of the brain evaluated and only at one or
two timepoints during and after irradiation (27–30).
Few reports describe interval follow-up using two-di-
mensional (2D) multivoxel spectroscopy (31) or 3D
spectroscopic imaging (32).
Our ultimate goal is to predict delayed neurological
sequelae of cranial RT by early assessment of metabolic
alterations in normal appearing brain using 2D chem-
ical shift imaging MRS (2D CSI MRS). We hypothesized
that structural degradation in cerebral tissue after RT
would be predicted by early changes in metabolic activ-
ity detectable by MRS before the development of neuro-
cognitive symptoms or anatomic changes seen on con-
ventional MRI.
In this prospective study we studied patients with
relatively stable tumors that were treated with conven-
tional fractionated RT at ordinary doses and did not
have obvious new radiation-induced radiographic ab-
normalities or evidence of early tumor growth after RT,
with the goal of evaluating early delayed RT effects on
normal-appearing brain.
MATERIALS AND METHODS
This prospective study involving MRI and 2D CSI MRS
was approved by the local Institutional Review Board.
All patients provided informed consent. Patients with
either low-grade glioma or benign tumors without pre-
vious cranial irradiation were eligible. Eleven patients
(10 men, 1 female, age range 25–71 years, mean 44
years of age) were enrolled. Their primary tumors were
low-grade gliomas (5), pituitary adenomas (4), meningi-
oma (1), and craniopharyngioma (1) (Table 1). All pa-
tients underwent standard 3D conformal fractionated
RT, resulting in partial brain irradiation (Fig. 1). All
patients were treated 1.8 Gy daily, Monday to Friday,
for 28–33 fractions, resulting in 50.4–59.4 Gy to the
tumor. MRI/MRS scans were acquired prior to RT, at 3
and 6 weeks during RT, and 1 month and 6 months
after the completion of RT to evaluate the impact on
radiation to normal brain tissue outside the tumor.
The conventional MRI brain protocol included: sagit-
tal and axial pre- and postgadolinium T1-weighted im-
ages, axial T2-weighted FLAIR (fluid attenuated inver-
sion recovery), T2-weighted images, diffusion-weighted
images, and postgadolinium T1-weighted coronal im-
ages. Spectroscopic data were acquired using point-
resolved (PRESS) 2D CSI performed on a 1.5T scanner
(LX EchoSpeed, GE Medical Systems, Milwaukee, WI)
with the following parameters: Probe-P, extended dy-
namic range, TE/TR 144/1500 msec, field of view (FOV)
24, thickness 10 mm, matrix 16  16, 1 NEX, with use
of saturation bands outside the FOV. The scan time was
6:30 minutes. The PRESS region was centered over the
midportion of the tumor and included normal-appear-
ing brain tissue on both sides of the tumor. The size of
the PRESS region varied from 8  3 cm2 to 8  10 cm2,
depending on the location of the tumor allowing for
coverage of regions receiving both high and low dose
RT. The metabolic spectra were analyzed using the ven-
dor software (Funtool 2, GE) with manual adjustment of
metabolic peak boundaries. Only spectra of 2D CSI
voxels from normal-appearing brain tissue outside the
tumor were analyzed in this study. In each patient,
spectra from a minimum of 14 voxels obtained from
scans during and after RT were paired with correspond-
ing voxels from scans prior to RT to assess changes in
metabolite levels. No voxels from cerebellum or pons
were included in the calculations. The metabolites of
N-acetylaspartate (NAA), choline (Cho), and creatine
(Cr) were evaluated, and the metabolic ratios NAA/Cr,
Table 1




Fx size (Gy) x
number of Fx
1 33/M Grade II gemistocytic astrocytoma 59.4 1.8  33
2 64/M Pituitary macroadenoma 50.4 1.8  28
3 55/M Sphenoid wing meningioma 54.0 1.8  30
4 29/M Craniopharyngioma 55.8 1.8  31
5 25/F Low grade glioma 54.0 1.8  30
6 71/M Null cell pituitary adenoma 50.4 1.8  28
7 30/M Grade II oligoastrocytoma 54.0 1.8  30
8 39/M Grade II mixed oligoastrocytoma 59.4 1.8  33
9 44/M Pituitary macroadenoma 50.4 1.8  28
10 55/M Grade II astrocytoma 54.0 1.8  30
11 33/M Pituitary macroadenoma 50.4 1.8  28
Fx, fraction.
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Figure 1. a–e: Axial post-Gd-DTPA T1-weighted images before RT (a) and 6 months after the completion of RT (b). The radiation
isodose contours are overlaid on post Gd-DTPA T1-weighted images (a). The large white boxes represent the VOIs for MRS
acquisition, and small white boxes depict the individual VOIs for spectral analysis. The three representative spectra prior to RT
(c), at 3 weeks of RT (d), and 6 months after RT (e) were from the corresponding bright white boxes in top panels. Color contours
denote isodose lines of radiation.
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Cho/Cr, and NAA/Cho were calculated. The metabolic
maps were digitally transferred for additional analysis
using FIAT (33), an integrated functional image analy-
sis software package developed in-house. FIAT is
equipped with a range of tools and features that allow
coregistration, mathematical manipulations, and eval-
uation of quantitative information.
We determined the areas under the metabolite peaks
and calculated the metabolite ratios in normal-appear-
ing brain parenchyma outside the tumor on conven-
tional pre- and postcontrast-enhanced T1-weighted,
T2-weighted, and FLAIR MRI. Timepoints studied were
at the baseline before RT, at 3 weeks and 6 weeks
during RT, and at 1 and 6 months after radiation treat-
ment.
Statistical Methods
The temporal changes of the metabolic ratios of Cho/
Cr, NAA/Cr, and NAA/Cho during and after RT were
compared to ones prior to RT by paired t-test. Bonfer-
roni correction was used for multiple comparisons, and
thereby a P-value of 0.0125 ( a/n  0.05/4) was
considered statistically significant. The correlations be-
tween the changes in the metabolic ratios and radiation
doses as well as the dose volumes were assessed by
linear regression, and again a P-value of 0.0125 was
considered statistically significant. The dose-volume
was defined as the volume of brain tissue that received
a dose greater than 40 Gy (V40) at the completion of RT
were used for the analysis as the effect of dose-volume.
RESULTS
Patient demographics, primary diagnosis and radiation
dosage are given in Table 1. All patients had stable
disease, ie, no interval change in tumor size, configu-
ration, contrast enhancement, or peritumoral edema in
the follow-up period following completion of RT.
Three patients did not have the 6-month follow-up
exam. In two other patients the anatomic locations of
the 2D MRS region acquired at either the 1-month or
6-month follow-up were not adequately aligned with the
pre-RT 2D MRS region, and thus these specific MRS
data timepoints were excluded from the final analysis.
MRI Findings
No interval change in size, configuration, or enhance-
ment of the tumor to suggest progression were noted in
the examined patients. Among the 11 patients studied,
no definite radiation-induced lesions were evident by
visual inspection of T2-weighted, FLAIR, and postgado-
linium T1-weighted images up to 6 months after RT. All
patients with low-grade glioma had hyperintense signal
on T2-weighted FLAIR images in the tumor and in its
vicinity that did not significantly change during the
6-month follow-up interval. In one patient with glioma,
mild scattered focal areas of increased T2/FLAIR signal
abnormalities were present in the centrum semiovale
and periventricular white matter prior to RT, consistent
with old ischemic changes. These areas demonstrated
no change over the 6 months of follow-up. No new areas
of signal abnormalities or pathological contrast en-
hancement suggestive of radiation-induced abnormali-
ties were present in the follow-up images. In patients
with pituitary adenomas and in the patient with cranio-
pharyngioma no signal abnormalities outside the tu-
mor were present before treatment, and no interval
change was seen during the 6 months of follow-up. The
patient with a meningioma demonstrated postsurgical
changes with no interval changes in T2 and FLAIR sig-
nal abnormalities over time.
MRS Findings
In this analysis, only voxels of normal-appearing brain
tissue were considered (Fig. 1). The quantity of patients
available for each timepoint was as follows: pretreat-
ment, 11 patients; week 3 of RT, 10 patients; last week
of RT, 9 patients; 1 month post-RT, 9 patients; and 6
months post-RT, 7 patients. The metabolic ratios of
NAA/Cr, Cho/Cr, and NAA/Cho in normal-appearing
brain tissue prior to RT were 1.43  0.04 (mean  SE),
1.29  0.03, and 1.18  0.03, respectively.
The metabolic ratios NAA/Cr and Cho/Cr in normal-
appearing brain tissues showed significant decreases
at week 3 of RT compared to the pre-RT values (Fig. 2).
The NAA/Cr ratio decreased by 0.19  0.05 at week 3
during RT (P  0.005), by 0.14  0.06 at the last week
of RT (P  0.02), by 0.14  0.05 (P  0.01) 1 month
after the completion of RT, and by 0.30  0.08 6
months after RT (P  0.0001, Fig. 2) compared to the
pre-RT values. The Cho/Cr ratio decreased by 0.27 
0.05 at week 3 during the RT (P  0.0001), by 0.11 
0.05 at the last week of RT (P  0.025), by 0.26  0.05
1 month after the completion of RT (P  0.0001), and
0.25  0.07 6 months after RT (P  0.001) compared
to the pre-RT ratios (Fig. 2). The NAA/Cho did not
change significantly during the RT, but increased sig-
nificantly 1 month after RT by 0.18  0.05 (P  0.001)
Figure 2. Differences of ratios of NAA/Cr (square), Cho/Cr
(triangle), and NAA/Cho (diamond) at week 3 and week 6
during RT, and 1 month and 6 months after the completion of
RT compared to the values prior to RT. Significant interval
changes were observed in NAA/Cr and Cho/Cr during and
after RT and in NAA/Cho at 1 month after RT. Error bar:
standard error of the mean.
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and eventually returned to the pre-RT baseline value at
6 months after RT (Fig. 2).
None of the changes in the metabolic ratios during
and after RT correlated with the local radiation dose
(P  0.05). However, the ratio Cho/Cr correlated with
the product of biologically corrected dose (equivalent to
2 Gy per fraction with a/b  2.5) received at the time
and the dose-volume, and this correlation was signifi-
cant at week 3 of RT (P  0.007), at the last week of RT
(P  0.005), and at 1 month after the completion of RT
(P  0.017). This relationship suggests that RT has a
greater effect on metabolites when a larger volume re-
ceives the high doses (Fig. 3). Even using the Bonferroni
correction, the correlation was significant at week 3 and
the last week of RT, and marginally significant at 1
month after RT. By 6 months after the completion of RT
the correlation was abolished (P  0.05).
DISCUSSION
Late radiation injury is the major, dose-limiting compli-
cation of brain irradiation, causing delayed neurologi-
cal complications and deficits in long-term survivors
(6–10). It has been suggested that MRS may serve as a
sensitive imaging tool to noninvasively detect neuro-
chemical changes as evidence of neurotoxicity in the
irradiated brain (23,24,26–29,31,32). The present
study demonstrates that significant alterations in brain
metabolites occur in normal-appearing human brain
parenchyma early during RT and that interval progres-
sion of some of these changes occurs over at least a
6-month period. This is especially evident by the inter-
val decrease in NAA/Cr ratios from the pretreatment
values of 1.39 by 0.19 at 3 weeks of RT and the
progressive decline by 0.30 at 6 months after the
completion of RT. It is conceivable that the observed
decreases in NAA/Cr and Cho/Cr ratios are partly at-
tributable to an increase in Cr; however, we expect the
drops in NAA and Cho levels to be genuine based on
visual inspection of the spectra and the fact that Cr has
often been used as an internal standard in other stud-
ies. The presumption that NAA decreases following ra-
diation is also supported by a previous study that dem-
onstrated a decrease in whole-brain NAA immediately
after prophylactic whole-brain RT in patients with lung
cancer (30). In addition, a decrease in the NAA concen-
tration with no change in the Cr concentration has been
demonstrated previously in studies of irradiated brain
(26–28). The metabolite NAA is predominantly present
in neurons and believed to represent a marker of neu-
ronal density and function. Creatine is a marker of
energy metabolism and is considered to be fairly stable
under most conditions even if some reports question
the stability of Cr in tumors, hypoxia, and other con-
founding factors (27,29). However, with the assumption
that Cr is stable, the metabolite is often used as a
denominator in ratio calculations. Therefore, the de-
crease in the NAA/Cr ratio is most likely due to neuro-
nal damage, neuronal cell death due to apoptosis, and
neuronal dysfunction secondary to the irradiation
rather than an elevation of the creatine, which also
would result in a decreased NAA/Cr ratio (4). Other
explanations such as neuronal response to blood–brain
barrier breakdown, edema, damaged oligodendrocytes,
demyelination, release of cytokines, and exposure to
inflammatory cells have also been suggested (34–36).
While several studies overall have demonstrated a
decrease in NAA after brain irradiation, there is some
controversy in the literature over the interval change of
the Cho metabolite. The Cho compound is correlated
with cell membrane biosynthesis and metabolic turn-
over in proliferative tissue (31). Observations of de-
creases in both Cho and Cho compounds, as well as the
decreased Cho/Cr ratio consistent with the present
study, have been reported previously (23,32,37). We
observed a decrease in Cho/Cr ratio early during RT,
and it remained decreased for the first 6 months after
RT, in agreement with previous reports (23,37). The
decrease of Cho/Cr below pretreatment levels at 6
months is also in accord with a previous study using 3D
MRS in which the authors demonstrated an initial in-
crease 2 months after RT followed by a decline below
pretreatment levels in patients receiving doses up to 50
Gy (32). It has been suggested that the decrease in Cho
seen in normal-appearing brain tissue might be due to
membrane damage in the myelin or the myelin-produc-
ing oligodendrocytes, accompanied by impaired tissue
perfusion (25). A previous diffusion tensor study
Figure 3. The relationships between the product of the local doses received at the time and the brain volume receiving high
doses (40 Gy) and the ratios of Cho/Cr at week 3 (a) and week 6 (b) during RT and 1 month after the completion of RT (c),
suggesting the interaction effect of the dose and the dose-volume on the metabolite.
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showed that demyelization becomes more evident over
time; these changes are seen at 1 month and progresses
up to 6 months after the end of RT (18). The decreases
that we observed in Cho/Cr after RT might reflect this
damage to irradiated normal-appearing brain second-
ary to the radiation. The damage to the normal-appear-
ing brain appears to stabilize over time with no further
decline in the Cho/Cr ratio at 6 months follow-up, at
least in patients receiving a dose of no more than 50 Gy.
Our findings of interval significant decrease in NAA/Cr
and Cho/Cr ratios are also in agreement with one of the
few previous reports of metabolic changes after prophy-
lactic irradiation in patients with acute lymphoblastic
leukemia (23). That study demonstrated a progressive
decrease in NAA/Cr and Cho/Cr ratios with increased
time since diagnosis. They found that the lower NAA/Cr
and Cho/Cr was associated with the presence of hemo-
siderin but not with imaging findings of leukoencepha-
lopathy. Another study, of children who received RT for
childhood leukemia or primary brain tumors (24),
found no interval differences in NAA/Cr or Cho/Cr, in
contrast to our study and other previous studies
(23,28). The differences between the findings presented
here and previous studies of young children (23,24)
could possibly be explained by differences in cellular
metabolism or radiation sensitivity of the young brain
compared to older individuals. Also, recent animal
studies have demonstrated significant differences in
brain metabolite concentrations in irradiated rat brain
(38) accompanied by worsening on behavioral tests in
the irradiated rats compared to sham-irradiated rats 54
weeks after RT (39).
Our study indicates that both the NAA and Cho me-
tabolites decrease during and early after RT. The pro-
gressive reduction in NAA over time suggests that the
process of neuronal damage continues long after the
completion of RT. However, to further evaluate changes
in the metabolites and especially to see if the changes
we describe in metabolite ratios could be due to an
increase in Cr, future studies should focus on more
quantitative analysis of absolute metabolite levels. Fu-
ture studies will also reveal if these metabolic changes
continue to progress after 6 months and if they corre-
late with the late delayed white matter signal abnormal-
ities commonly seen on MRI.
Overall our study did not demonstrate any significant
dose dependence in normal-appearing brain tissue.
This is in contrast to a few existing reports on dose-
dependent changes in metabolic ratios (32,40). How-
ever, the present study demonstrated that Cho/Cr ra-
tios from week 3 during the course of RT and 1 month
after the completion of RT were significantly correlated
with the product of biologically corrected dose received
at the time and the volume of the brain that received
high doses. These findings suggest that there is an
interaction effect of the dose and the dose-volume on
the metabolites. Possible explanations for our finding of
no relationship between changes in metabolites and RT
dose include our limited number of patients, limited
data collection, and limited signal-to-noise ratio. An-
other possible explanation is the heterogeneity of our
sample, especially in brain regions studied, but also in
tumor histopathology. The reduction in NAA could be
secondary to other neurotoxicities from RT, for exam-
ple, blood–brain barrier opening or white matter demy-
elination. Blood–brain barrier opening occurs early
with doses as small as 30 Gy, and it results in abnormal
entry of chemicals from the blood into brain tissue. In
white matter, early focal and dose-dependent changes
in diffusion followed by diffuse changes have been re-
ported (18). The future work will analyze the relation-
ship between the blood–brain barrier, white matter in-
jury, and neuronal injury to determine the temporal
evolution of radiation-induced cerebral injury as well as
early indicators of this injury.
While it would be of interest to correlate MRS changes
to changes in cognitive function as demonstrated by
neurocognitive tests, we did not feel that our data were
sufficient for this analysis. The heterogeneous locations
of the tumors resulted in different localizations of the
2D spectroscopic VOIs that generated data from vari-
ous brain regions. Data were obtained in some of our
patients from the temporal lobe and in others from the
frontal lobe, but in no cases from both regions, and
therefore comparison with metabolic ratios and neuro-
cognitive tests became implausible.
The heterogeneous tumor histopathology could be
considered a limitation of this study. However, none of
the tumors demonstrated any change over the period of
study, nor was there any change in peritumoral edema
in those cases where this was present. We did not study
the tumor or the edema but placed ROIs only in normal-
appearing brain. Another potential source of difference
compared to previous reports is tumor diagnosis. We
studied only patients with low-grade gliomas and low-
grade tumors to have a sample likely to remain stable
over the period of study. None of these patients had
ongoing steroid treatment, which might confound the
study of patients with high-grade gliomas.
We chose to use the 2D CSI MRS with the PRESS
technique and an intermediate echo time of 144 ms to
cover a larger irradiated area. We did not use a limited
single voxel spectroscopy technique (SVS) even though
SVS may be favorable for quantification of metabolites.
For future work we plan to add SVS with short echo
time for quantification of individual metabolites over
time and to determine if the changes seen in the me-
tabolites might be due to gliosis by analysis of the my-
oinositol resonance at short echo time. In the present
study, regional variations in spectra were not consid-
ered. However, inspection disclosed no changes in the
location of the spectral regions for 6 months after RT
occurred. In addition, changes in T1 and T2 relaxation
times of metabolites were also not considered in this
study. However, we have not calculated the individual
metabolite concentrations, only the metabolic ratios. In
the future we aim to expand our study to evaluate
metabolite changes occurring over a longer time period
by following the present patients up to 18 months to
evaluate late delayed effects of RT.
Studies of normal volunteers or of nonirradiated
brain regions would permit evaluation of scanner sta-
bility over time to verify stability of the metabolic ratio
measurements. We did not study normal volunteers or
nonirradiated regions and thus cannot exclude the pos-
sibility that scanner instability could account for some
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of the changes seen. We plan to include normal volun-
teers in future work.
In conclusion, the results of this prospective study
suggest that occult injury to the normal brain begins
during RT and remains evident for at least 6 months.
This study also supports the hypothesis that MRS is
sensitive for early detection of metabolic changes in
normal brain tissue undergoing radiation. The ability of
MRS to detect progressive neuronal injury suggests
that MRS might be able to compare the effects of differ-
ent RT regimens and to evaluate neuroprotective ther-
apies with the potential to minimize the neurotoxicity of
brain RT.
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